|Bid||0.0000 x 1100|
|Ask||0.0000 x 900|
|Day's Range||4.9500 - 5.3958|
|52 Week Range||3.3200 - 8.4900|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
President and CEO of Vaccinex Inc (30-Year Financial, Insider Trades) Maurice Zauderer (insider trades) bought 183,824 shares of VCNX on 07/30/2019 at an average price of $4.08 a share. Continue reading...
A look at the shareholders of Vaccinex, Inc. (NASDAQ:VCNX) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning Read More...